TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06783439

Intervention type: OTHER
Intervention: Ultrasound
Description: The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.

Intervention type: OTHER
Intervention: Ultrasound
Description: The ultrasound probe will be placed parallel to the body of the piriformis muscle on an imaginary line drawn from the sacrum to the greater trochanter of the femur. This area is also the sensitive area of the patients during the examination with pressure, and when the US probe is in this position, the subcutaneous fat tissue, gluteus maximus muscle, piriformis muscle, and the upper and lower borders of the sciatic nerve will be displayed in order from superficial to deep. First, the maximum thickness of the piriformis muscle body will be measured, then the thickness of the sciatic nerve will be measured, and the same measurements will be applied to the patient's asymptomatic hip, and the measurements will be recorded.
Study: NCT06786806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gamified Infection Control Education Program
Description: A four-week educational program integrating gamification techniques such as physical games, case studies, and escape rooms to teach infection control practices.Designed to enhance engagement, learning motivation, and cognitive achievement among nursing students.

Intervention type: OTHER
Group type: OTHER
Intervention: Traditional Lecture-Based Instruction
Description: Standard didactic teaching method focusing on infection control principles without incorporating gamification. Served as the comparator to evaluate the effectiveness of the gamified program.
Study: NCT06787911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donafeib with Sintilimab
Description: Patients receive Donafenib and PD-1 antibody Sintilimab
Study: NCT06784973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obeldesivir Placebo
Description: Administered orally
Study: NCT06786325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: PEX010 is the Psilocybin produced by Filament

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psilocybin
Description: PEX010 is the Psilocybin produced by Filament
Study: NCT06784258

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: General Anesthesia (control group)
Description: The patient will undergo conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/kg BB. After that the patient will be intubated

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: General Anesthesia combined with epidural anesthesia
Description: The patient will undergo epidural anesthesia first with an epidural catheter inserted through a Tuohy needle and ensuring that the length of the multihole epidural catheter that enters the epidural space is 5-6 cm. After that, the patient underwent conventional general anesthesia with a regimen of intravenous fentanyl 1-2 mcg/kg BW, propofol 2-3 ml/kg BW, and muscle relaxants for intubation, such as atracurium 0.5 mg/kg BW or rocuronium 0.6 mg/ kg BW. After that the patient will be intubated. The patient will be given local anesthesia Bupivacaine 0.25% in increments to the desired volume according to the desired height of the segmental block. Local anesthetic medication will be given intermittently every 2 hours
Study: NCT06782516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System of Care - combination of algorithm and Brief Contact Intervention
Description: Case managers see the Native-RISE algorithm classification and Clinical Providers receive a risk notification. A resource card is provided to the participant.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: System of Care - combination of algorithm and Brief Contact Intervention
Description: Case managers see the Native-RISE algorithm classification and Clinical Providers receive a risk notification. A resource card is provided to the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator - Provider notification of risk status
Description: Clinical Providers receive a risk notification and a resource card is provided to the participant.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator - Provider notification of risk status
Description: Clinical Providers receive a risk notification and a resource card is provided to the participant.
Study: NCT06787287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified compression method
Description: In the experimental group, an improved compression method was adopted. A thick gauze block of 9cm\*16cm\*8mm was folded three times and placed at the puncture site of the patient's radial artery, and a spiral radial artery hemostatic device was placed above it. The control group was treated with traditional compression method, and the spiral radial artery hemostat was applied directly at the radial artery puncture
Study: NCT06029894

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Citicoline Supplement
Description: Participants with MCI will receive dietary citicoline supplements. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants with MCI will receive a placebo supplement. Subjective sleep measures will be measured via the Pittsburgh Sleep Quality Index (for measurement of sleep quality) and Epworth Sleepiness Scale (for measurement of sleepiness). Cognition will be measured by Rey Auditory Verbal Learning Test (RAVLT), Trail Making Test (TMT) Parts A \& B, and the Montreal Cognitive Assessment (MOCA). Participants will complete all questionnaires at baseline and at follow-up at 3 months. Participants will undergo a blood draw of approximately 20 ml at baseline and at follow-up.
Study: NCT06783023

Intervention type: OTHER
Intervention: validity and reliability study
Description: In the study, which will include at least 24 individuals with CIED determined by power analysis, unassisted arm exercise capacity and arm function/endurance, maximum arm exercise capacity, double product, heart recovery, comorbidity level, hand grip strength, fear of movement, activities of daily living and quality of life will be evaluated.
Study: NCT06787950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN-3186
Description: ASN-3186 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN-3186
Description: ASN-3186 will be administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASN-3186
Description: ASN-3186 will be administered orally.
Study: NCT06786455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-1905 Injection
Description: SHR-1905 Injection,medium dose, administered by subcutaneous injection;
Study: NCT06783569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JR8603
Description: IV infusion on Days 1, 8, and 15 of continuous 28-day cycles
Study: NCT06784180

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 200 mcg intrathecal morphine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: Intrathecal 0.75% bupivacine in 8.25% dextrose (Dose determined by weight, height, gestational age)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 15 mcg intrathecal fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: 15 mcg intrathecal fentanyl

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Description: 100 mcg intrathecal hydromorphone
Study: NCT06782594

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate Injection(high)
Description: Mosapride Citrate Injection, iv, 8mg, bid, for 3 to 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mosapride Citrate Injection(low)
Description: Mosapride Citrate Injection, iv, 4mg, bid, for 3 to 5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, iv, bid, for 3 to 5 days
Study: NCT06785194

Intervention type: DEVICE
Intervention: REVIVE samfilcon B custom toric contact lenses
Description: REVIVE samfilcon B custom toric contact lenses
Study: NCT06785766

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga-Based Exercise Program
Description: This intervention is an 8-week yoga-based exercise program conducted with 60-minute sessions twice a week. The program aims to improve flexibility, mobility, and overall well-being. Each session consists of 5 minutes of warm-up, 5 minutes of breathing exercises, 40 minutes of yoga postures, 5 minutes of deep relaxation, and 5 minutes of meditation. The intervention adapts yoga postures based on participants' individual needs, offering a flexible approach. The difficulty of the yoga flows gradually increases over the 8 weeks. When necessary, postures are adapted using props like blocks, straps, blankets, and chairs. A physiotherapist guides participants, demonstrating correct techniques and providing verbal instructions. This program combines yoga, breathing exercises, and meditation to enhance physical and mental well-being, promoting long-term health benefits.
Study: NCT06784726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Odronextamab
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and oral or rectal swab samples

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Chimeric Antigen Receptor T-Cell Therapy
Description: Undergo CAR-T cell therapy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Leukapheresis
Description: Undergo leukapheresis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Puncture
Description: Undergo lumbar puncture

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tissue biopsy
Study: NCT06784557

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin 40mg
Description: High intensity HMG-CoA reductase inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20mg+Ezetimibe 10mg
Description: Moderate intensity HMG-CoA reductase inhibitor plus NPC1L1 antagonist
Study: NCT06612502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fascia gun ( Short-time PMT )
Description: The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The short time PMT was applied for 2.5 minutes per muscle site for a total of 25 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fascia gun ( Long-time PMT )
Description: The PMT was performed by the two physiotherapists using an OUTSO 06® Fascia Gun equipped with a 5 cm diameter soft attachment head and the vibration frequency was 53 Hz. The targeted muscles included the quadriceps, adductors, hamstrings, iliotibial band, and gluteal muscles for both sides. Throughout the PMT, the physiotherapists carefully maintained a consistent level of moderate pressure on the skin, and followed the direction of the muscle fibers. The long time PMT was applied for 4 minutes per muscle site for a total of 40 minutes.
Study: NCT06611527

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PS+PEEP group
Description: Application of 4 sets of 20 repetitions with PS to provide a tidal volume equal to 10ml/kg of predicted body weight, PEEP equal to 10 cmH2O, and inspired oxygen fraction (FiO2) to achieve peripheral oxygen saturation (SpO2) between 92-94%

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP group
Description: Application of CPAP of 10 cmH2O with FiO2 to achieve SpO2 between 92-94% for 30 minutes.
Study: NCT04817267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: reSET-O app
Description: The reSET-O app, a prescription digital therapeutic, provides cognitive behavioral therapy for opioid use disorder. The app provides psychoeducation related to opioid use, coping skills, and skills to avoid relapse.
Study: NCT06612190

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMS
Description: TMS treatment in this study indicates a non-invasive procedure called transcranial magnetic simulation (TMS) on visual cortex. The treatment intensity is set as 80% of the threshold of each participant. The treatment will be conducted every day for consecutive 5 days.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The sham group will be given no real magnetic stimulation.
Study: NCT05782972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dapagliflozin (Forxiga)
Description: The participants received oral dapagliflozin (Forxiga) 10 mg/day for 24 weeks.
Study: NCT06269146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Pill
Description: The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pramipexole Pill
Description: The study drug, pramipexole, is an FDA-approved medication for the treatment of Parkinson's and restless leg syndrome. Pramipexole (Mirapex) tablets are taken orally, with or without food.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Pill
Description: Placebo will match the study drug in mode of administration, color, size, and taste.
Study: NCT04788849

Intervention type: DIAGNOSTIC_TEST
Intervention: BD Onclarity™ HPV assay
Description: Women will be asked to self-collect first-void urine using Copan's UriSponge™ 8E031S100 and vaginal swabs using Copan's FLOQSwabs® 5E089N. All samples will be tested with BD Onclarity™ HPV assay. HPV test results on self-collected samples will be compared to those obtained when testing clinician-collected cervical sample
Study: NCT06478082

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home-based virtual reality training
Description: 8-week training with an advised frequency of 30 minutes per day, for 5 days per week.
Study: NCT06337734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AI-Driven Lifestyle Coaching Program
Description: The intervention provides participants with automated and personalized lifestyle recommendations involving a sophisticated analytics engine using advanced statistics and machine learning.
Study: NCT06144450

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Web-Based Monitoring Program
Description: The research will be carried out in three stages; (1) creating the content of the follow-up program, (2) designing the web page, (3) implementing the program with mothers. The topics to be included in the monitoring program will be prepared within the framework of the Empowerment Model. Knowledge and attitude-self-efficacy will be tried to be increased with the modules to be prepared. Accordingly, the program is planned to consist of 3 modules. These are Preparation for Hospital Discharge Module, Transitional Care Module and Home Care Module. The presented modules will be made accessible to mothers in the experimental group through a website. The modules will be completed in order and the necessary forms and follow-ups will be completed at the end of each module.
Study: NCT06443515

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: lung ultrasound
Description: Lung ultrasound examinations will be performed within 6 hours before and after blood transfusion to assess interstitial-alveolar fluid retention and calculate a LUS score
Study: NCT04730752

Intervention type: DIAGNOSTIC_TEST
Intervention: Appendicitis Inflammatory Response
Description: A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters

Intervention type: DIAGNOSTIC_TEST
Intervention: Adult Appendicitis Score
Description: A scoring system used to diagnose acute appendicitis. It consists of clinical findings and laboratory parameters
Study: NCT06341062

Intervention type: OTHER
Intervention: Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound
Description: Renal microcirculation quantitatively assessed by Contrast-enhanced ultrasound before hospital discharge
Study: NCT05496465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARS-1
Description: A single treatment of ARS-1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARS-1
Description: A single treatment of ARS-1.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A single treatment of placebo nasal spray
Study: NCT05195099

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: respiratory treatment
Description: Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: respiratory treatment
Description: Respiratory treatment based on aerobic exercise and treatment of the musculature to reduce dyspnoea and increase the capacity for exertion, neurorehabilitative treatment focusing on the sense of smell and taste to on the sense of smell and taste to increase sensitivity in post Covid-19 subjects.
Study: NCT05511259

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: Square stepping exercise
Study: NCT06174194

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tulsi Gum
Description: The intervention involves participants chewing a specially formulated gum known as Tulsi Gum for 5 minutes. Tulsi Gum contains Tulsi extract, a natural substance derived from the Tulsi plant. This extract is recognized for its potential antimicrobial properties. Participants are then required to discard the gum. The study aims to assess the effect of Tulsi Gum on salivary Streptococcus mutans count in children aged 4 to 11 years. This assessment contributes to understanding the potential of Tulsi Gum in preventing dental caries in children.